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Background: Cardiac resynchronization therapy (CRT) has emerged as an effective 
treatment strategy for patients with advanced heart failure (New York Heart Association 
classes II–IV heart failure, left ventricular ejection fraction (LVEF) ≤ 35%, and a QRS 
duration ≥ 120 ms). Approximately 30% of patients do not respond favourably to CRT. In 
recent years, the proportion of patients who respond favourably to CRT did not increase 
significantly. CRT is merely electrical therapy that improves left ventricular (LV) 
mechanical dyssynchrony by changing the sequence of electrical activation and restoring 
electrical synchrony. Therefore, ECG parameters of conduction anomalies and electrical 
dyssynchrony play an evolving and important role in understanding the mechanism of CRT 
response. Little is known about the effect of CRT on ventricular repolarization parameters. 
There are some data about the increase repolarization heterogeneity after CRT and 
potentially its proarrhytmic effect. On the other hand, some studies found amelioration of 
repolarization heterogeneity after CRT. However, interdependence between electrical and 
mechanical remodelling and time course of electrical remodelling have not been fully 
investigated. The present thesis evaluated the value of different ECG parameters in heart 
failure patients treated with CRT and clarified the time course and relationship between 
electrical and mechanical reverse remodelling after CRT.  
Methods:  The study population was selected from heart failure patients treated with CRT 
according to contemporary guidelines in University medical centre Ljubljana. All patients 
included in the study had transthoracic two-dimensional echocardiography performed at 
baseline and at follow-up visits (1, 3, 6, 9 and 12 months after implantation). Resting supine 
12-lead ECGs and 20-minutes high-resolution Holter ECG were recorded before and after 
CRT implantation.  At follow-ups, CRT was temporarily reprogrammed to VVI 40 bpm to 




was defined as significant electrical remodelling (ER). Relative change in QRS duration was 
defined as the difference between post-implant QRS duration and baseline QRS duration 
divided by baseline QRS duration expressed in percent. All ventricular repolarization 
parameters (T-wave amplitude variability [TAV], QTa interval [QT apex], QTe interval [QT 
end], dispersion of QT, Tpeak to Tend interval [TpTe], and TpTe /QT ratio) were assessed 
from high-resolution 20-minutes ECG recordings. Ventricular tachyarrhythmia episodes 
(VTs) were classified as sustained ventricular tachycardia with appropriate ICD therapy or 
ventricular fibrillation. Heart failure hospitalization, cardiovascular death and cardiac 
transplantation were used as a combined end point to observe clinical outcome. 
Results:  
I. The association of electrocardiographic parameters from 12-leads ECG and response to 
CRT 
The study population consisted of 101 patients with a mean age of 63.2 ± 10.9 years (66 
(65.2%) males, 37 (36.6%) ischaemic aetiology, 77 patients (76.2%) in NYHA class III). 
After 12 months of biventricular pacing, 32 patients (31.7%) fulfilled the echocardiographic 
criteria of super-response (a relative reduction in LVESV ≥ 30%). There were no statistically 
significant differences in baseline ECG parameters when super-responder group was 
compared with non-super-responder group. Post-implant paced QRS duration was shorter in 
super-responder group (148 ± 22 ms vs. 162 ± 28 ms; P = 0.010). Additionally, only in super-
responders significant QRS reduction was observed after implantation (super-responders: 
from 167 ± 26 ms to 148 ± 22 ms; P=0.010 vs. non-super-responders: from 165 ± 27 ms to 
162 ± 28 ms; P = 0.536). Relative shortening of QRS complex was significantly higher in 
super-responders (12.1% (6.8-22.2) vs. 1.7% ([-11.9] to 11.8); P = 0.005). Only relative QRS 
shortening remained independently related to super-response to CRT in multivariable model 
adjusting for NYHA class, normal axis and LBBB with mid-QRS notching.  
 
II. The effect of cardiac resynchronization therapy on ventricular repolarization parameters 
and their relation to ventricular tachyarrhythmias 
Sixty-four patients (mean age of 63.9 ± 10.9 years, 47 (73%) males, 23 (36%) ischaemic 
cardiomyopathy) were enrolled in the analysis. Response to CRT, predefined as a relative 
reduction in LVESV ≥ 15%, was observed in 33 patients (51.6%). There were significant 




implantation. Significant changes over time was observed in QTec (P < 0.001), TpTe (P < 
0.001), TpTe/QT ratio (P < 0.001) and dispersion of QTe (P < 0.014), whereas TAV values 
and QTa intervals were unchanged over first year after CRT. All repolarization parameters 
showed a similar pattern of changes with the increased repolarization heterogeneity in first 
months after CRT implantation, which then declined over time. Significant differences in 
repolarization parameters were observed between patients with and those without 
echocardiographic response to CRT. In responder group, despite significant prolongation in 
the first months, decline of repolarization parameters were noted during further follow-ups. 
On the other hand, in non-responder group progressive increase of repolarization parameters 
at follow-ups compared with pre-implant value were observed. Responder and non-
responder group had similar pre-implant value of all repolarization parameters. Significant 
difference between groups in repolarization parameters was detected after 6 months of 
biventricular pacing. Appropriate device therapy was observed in 10 patients (15.6%) within 
1 year after CRT implantation. More than half of the patients (60%) had VTs within the first 
month after CRT implantation. Distribution of VTs with the highest occurrence in the first 
month corresponded with the highest repolarization heterogeneity in the same period.  
 
III. Time course and relationship between electrical and mechanical reverse remodelling 
after CRT  
The study population included 62 patients (50 (81%) males, with mean age of 65.7 ± 10.3 
years). There were significant changes in native QRS duration during 12 months after 
implantation (P = 0.003). Significant shortening of QRS duration was already observed at 1 
month after CRT (pre-implant vs. 1 month: 185ms (175-194) vs. 180ms (170-186); P < 
0.05), which persisted during further follow-ups. On the other hand, progressive LV 
structural remodelling was observed during 12 months with continuous reductions in LV 
volumes and improvement of LVEF (P < 0.001, for all). However, significant 
echocardiographic changes were observed only after 3 months of CRT (EDV: 231 ml (191-
280) vs. 200 ml (167-267), P < 0.05; ESV: 167 ml (137-206) vs. 140 ml (112-196), P < 0.05; 
EF: 27% (24-31) vs. 31% (24-38), P < 0.05). In patients with ER, the reductions in QRS 
duration were already pronounced after one month of CRT (pre-implant vs. 1 month: 190 
ms [179-196] vs. 180 ms [173-186]; P < 0.001) and persisted over follow-up. There were no 
changes in QRS duration during follow-ups in patients without ER. One month after 




patients with ER demonstrated progressive reverse LV remodelling compared with patients 
without ER. During a median follow-up of 27 months (18–37 months), the combined end 
point was observed in 15 (24.2%) patients. Compared with patients without ER, a superior 
survival free from combined end point was observed among patients with ER (chi-squared 
= 4.85, log-rank P = 0.028).  
Conclusion: Some baseline ECG parameters from 12-leads ECG recording are associated 
with increased degree of echocardiographic response after CRT. Absolute post-implant QRS 
duration and acute relative shortening of QRS duration after initiation of CRT were 
correlated with super-response. However, there were dynamic changes of repolarization 
parameters of native conduction during 12 months after CRT. Increase repolarization 
heterogeneity in the first month after CRT corresponded with the high rate of VTs in the 
same periods. Additionally, electrical remodelling of native conduction is achieved before 
mechanical remodelling. Patients with electrical remodelling had better clinical outcome 






Izhodišča: Atrio - biventikularna elektrostimulacija srca oz. resinhronizacijsko zdravljenje 
(CRT; angl. cardiac resynchronization therapy) je uveljavljena metoda zdravljenja bolnikov 
z napredovalim srčnim popuščanjem. Po zadnjih priporočilih evropskega kardiološkega 
združenja so za ta način zdravljenja primerni bolniki, ki so ob optimalnemu zdravljenju z 
zdravili v funkcijskem razredu NYHA II- IV, imajo močno oslabljen iztisni delež levega 
prekata (LVEF; angl. left ventricular ejection fraction ≤ 35%) in širino kompleksa QRS ≥ 
120 ms. Kljub dokaj jasnim kriterijem je še vedno približno 30% bolnikov, ki se na takšen 
način zdravljenja ne odzovejo. V zadnjih letih se delež bolnikov, ki se ugodno odzivajo na 
CRT ni bistveno povečal. CRT je prvenstveno električna stimulacija srca, ki povzroči najprej 
usklajeno električno aktivacijo levega prekata (LV), le-to pa posledično vodi v usklajeno 
mehansko aktivacijo LV. Zato ni presenetljivo, da imajo pomembno vlogo v  razumevanju 
uspešnosti zdravljenja s CRT elektrokardiografski parametri, ki označujejo motnje 
prevajanja in električno dissinhronijo. O vplivu CRT na EKG parametre prekatne 
repolarizacije ni veliko podatkov. Nekateri podatki kažejo na povečanje heterogenosti 
repolarizacije in možnosti prekatnih motenj ritma, medtem ko nekatere druge raziskave 
dokazujejo zmanjšanje heterogenosti repolarizacije po CRT. Zdravljenje s CRT vpliva tako 
na proces reverzne električne remodelacije kot tudi na mehansko remodelacijo srca. 
Soodvisnost doseganja električne in mehanske remodelacije ter časovni okvir električne 
remodelacije še niso v celoti raziskani. Z doktorsko dizertacijo želimo ovrednotiti pomen 
različnih EKG parametrov pri zdravljenju srčnega popuščanja s CRT ter opredeliti časovno 
povezavo med električno in mehansko remodelacijo po CRT. 
Metode: Preiskovano skupino so sestavljali bolniki s srčnim popuščanjem, ki smo jim v 
Univerzitetnem kliničnem centru Ljubljana vstavili napravo za biventrikularno 




vstavitvijo in ob kontrolah (1, 3, 6, 9 in 12 mesecev po vstavitvi) so imeli bolniki opravljeno 
ultrazvočno preiskavo srca in posnetek standardnega 12-kanalnega EKG in 20-minutnega 
visoko ločljivostnega Holter EKG. Ob kontrolah smo za čas snemanja EKG začasno 
prenastavili CRT na nastavitve, ki so omogočale posnetek v lastnem sinusnem ritmu oz. 
nestimuliran EKG posnetek. Električno remodelacijo (ER) smo opredelili kot zmanjšanje 
nativnega trajanja kompleksa QRS ≥ 10 ms. Določili smo tudi relativno skrajšanje 
kompleksa QRS (
 𝑄𝑅𝑆 𝑝𝑜 𝑣𝑠𝑡𝑎𝑣𝑖𝑡𝑣𝑖− 𝑄𝑅𝑆 𝑝𝑟𝑒𝑑 𝑣𝑠𝑡𝑎𝑣𝑖𝑡𝑣𝑖𝑗𝑜
 𝑄𝑅𝑆 𝑝𝑟𝑒𝑑 𝑣𝑠𝑡𝑎𝑣𝑖𝑡𝑣𝑖𝑗𝑜
), ki smo ga izrazili v odstotkih. 
Parametre prekatne repolarizacije smo določili iz 20-minutnega visokoločljivostnega Holter 
EKG posnetka; analizirali smo variabilnost amplitude vala T (TAV), interval QTa (QT 
apeks), interval QTe (QT konec), disperzijo omenjenih intervalov,  interval od apeksa do 
konca trajanja vala T (TpTe) in razmerje TpTe/QT. Opredelili smo pojavnost prekatnih 
motenj ritma; in sicer vse prekatne tahikardije, ki so bile prekinjene z aktivacijo ICD in vse 
epizode prekatne fibrilacije. Po vstavitvi smo beležili srčno-žilno umrljivost, hospitalizacijo 
zaradi poslabšanja srčnega popuščanja in potrebo po presaditvi srca (skupni opazovani 
dogodek). 
Rezultati: 
I. Povezava med elektrokardiografskimi parametri iz 12-kanalnega EKG in odzivom 
na zdravljenje 
Analizirali smo 101 bolnika (starost 63.2 ± 10.9 let, 66 (65.2%) moških, 37 bolnikov (36.6%) 
z ishemično kardiomiopatijo, 77 bolnikov (76.2%) v funkcijskem razredu NYHA III) z 
vstavljenim CRT. Eno leto po vstavitvi smo pri 32 bolnikih (31.7%) ugotovili nadpovprečno 
dober odgovor na zdravljenje (angl. super-response; relativno zmanjšanje končnega 
sistoličnega volumna LV (LVESV) ≥ 30%). Med skupino z nadpovprečnim odgovorom na 
zdravljenje in preostalimi bolniki ni bilo pomembnih razlik v EKG parametrih pred 
vstavitvijo CRT. Trajanje stimuliranega kompleksa QRS neposredno po vstavitvi CRT pa je 
bila v skupini z nadpovprečnim odgovorom na zdravljenje pomembno krajše (148 ± 22 ms 
vs. 162 ± 28 ms; P = 0.010). Pomembno skrajšanje trajanja kompleksa QRS smo beležili v 
skupini z nadpovprečnim odgovorom na zdravljenje (skupina z nadpovprečnim odgovorom 
na zdravljenje: iz 167 ± 26 ms na 148 ± 22 ms; P = 0.010 vs. skupina brez nadpovprečnega 
odgovora na zdravljenje: iz 165 ± 27 ms na 162 ± 28 ms; P = 0.536). Tudi relativno skrajšanje 




(12.1% (6.8-22.2) vs. 1.7% ([-11.9] do 11.8); P = 0.005). V mulitvariantni analizi, je ob 
upoštevanju funkcijskega razreda NYHA, levokračnega bloka in normalne srčne osi, 
relativno skrajšanje kompleksa QRS ostal edini neodvisni parameter povezan z 
nadpovprečnim odgovorom na zdravljenje s CRT.  
 
II. Vpliv resinhronizacijskega zdravljenja na parametre prekatne repolarizacije in povezava 
z prekatnimi motnjami ritma  
V analizo smo vključili 64 bolnikov (starost  63.9 ± 10.9 let, 47 (73%) moških, 23 bolnikov 
(36%) z ishemično kardiomiopatijo). Pri 33 bolnikih (51.6%) smo ugotovili pozitiven 
odgovor na zdravljenje (izboljšanje LVESV ≥ 15%). V prvem letu po vstavitvi so se 
parametri prekatne repolarizacije pomembno spremenili. Pomembno spremembo smo 
beležili pri intervalu QTec (P < 0.001), TpTe (P < 0.001), razmerju TpTe/QT (P < 0.001) in 
disperziji intervala QTe (P < 0.014), medtem ko pri TAV in intervalu QTa pomembne 
spremembe nismo beležili. V prvih mesecih po vstavitvi CRT smo pri vseh parametrih 
repolarizacije beležili povečanje heterogenosti repolarizacije, ki pa se je nato znižala tekom 
nadaljnjega opazovanja. Bolniki z odgovorom na zdravljenje in bolniki, pri katerih nismo 
beležili odgovora na zdravljenje s CRT, so imeli pomembno različne spremembe parametrov 
repolarizacije v opazovanem obdobju. Pri bolnikih z odzivom na zdravljenje smo sicer 
beležili povečanje heterogenosti repolarizacije v prvih mesecih, a se je le-ta nato pomembno 
znižala. Medtem ko so se pri bolnikih brez odgovora na zdravljenje, parametri repolarizacije 
pomembno podaljševali tekom celotnega opazovanega obdobja. Obe skupini bolnikov sta 
imeli primerljive vrednosti parametrov repolarizacije pred vstavitvijo CRT. Pomembna 
razlika v parametrih repolarizacije med skupinama se je nato pokazala po 6 mesecih 
biventrikularne stimulacije. V prvem letu po implantaciji smo pri 10 bolnikih (15.6%) 
beležili prekatne motnje ritma. Več kot polovica teh bolnikov (60%) je imela motnje ritma 
v prvem mesecu po vstavitvi CRT. Porazdelitev motenj ritma z največjo pojavnostjo v prvem 
mesecu je ustrezala najvišjim vrednostim heterogenosti repolarizacije v istem obdobju.  
 
III. Časovni potek in povezava med električno in mehansko remodelacijo po 
resinhronizacijskem zdravljenju  
V raziskavo smo vključili 62 bolnikov (starost  65.7 ± 10.3  let, 50 (81%) moških). V prvem 
letu po vstavitvi smo beležili pomembo spremembo trajanja nativnega kompleksa QRS (P = 




QRS (185 ms [175-194] vs. 180 ms [170-194]; P < 0.001), ki je nato vztrajalo v nadaljnjem 
opazovanem obdobju. Medtem ko smo mehansko remodelacijo LV, z zmanjšanjem volumna 
in izboljšanjem LVEF, beležili tekom celega leta po vstavitvi CRT (P < 0.001). Statistično 
pomembne strukturne spremembe so bile sicer opazne šele 3 mesece po vstavitvi CRT 
(EDV: 231 ml (191-280) vs. 200 ml (167-267), P < 0.05; ESV: 167 ml (137-206) vs. 140 ml 
(112-196), P < 0.05; EF: 27% (24-31) vs. 31% (24-38), P < 0.05). V skupini bolnikov z ER, 
je bilo izrazito skrajšanje trajanja kompleksa QRS beleženo v 1 mesecu po vstavitvi (pred 
vstavitvijo vs. 1 mesec po vstavitvi: 190 ms [179-196] vs. 180 ms [173-186]; P < 0.001), 
medtem ko pri bolnikih brez ER, pomembne spremembe trajanje kompleksa QRS nismo 
beležili. V prvem mesecu po vstavitvi je bila relativna sprememba ESV pri obeh skupinah, 
z in brez ER, primerljiva. V nadaljnjem opazovanem obdobju smo samo pri bolnikih z ER 
beležili pomembno reverzno remodelacijo LV. Mediani čas spremljanja bolnikov je bil 27 
mesecev (18–37); v tem obdobju smo skupni opazovani dogodek beležili pri 15 bolnikih 
(24.2%).  Bolniki z ER so imeli boljše preživetje do skupnega opazovanega dogodka kot 
bolniki brez ER (log-rank P = 0.028). 
Zaključki: Določeni parametri iz 12-kanalnega EKG zapisa so povezani z boljšim odzivom 
na zdravljenje po CRT. Absolutno trajanje stimuliranega kompleksa QRS in relativno 
skrajšanje trajanja kompleksa QRS neposredno po vstavitvi so povezani z nadpovprečnim 
odgovorom na zdravljenje s CRT. V prvem letu po vstavitvi CRT beležimo dinamične 
spremembe parametrov repolarizacije. Najvišje vrednosti heterogenosti repolarizacije v 
prvem mesecu po vstavitvi ustrezajo največji pojavnosti prekatnih motenj ritma v istem 
obdobju. Po vstavitvi CRT je ER dosežena preden so beležene pomembne volumetrične 
spremembe LV. Bolniki z doseženo ER po vstavitvi CRT imajo boljši klinični izid 






Current Practice of Cardiac Resynchronization Therapy 
After first clinical application of biventricular pacing in patient with severe congestive heart 
failure in the mid 1990s, cardiac resynchronisation therapy (CRT) has become nowadays an 
essential therapy for patients with advanced heart failure (HF) and left ventricular (LV) 
conduction delay.1,2 Over the last two decades, several multicentre randomized trials have 
firmly proved consistent improvements in quality of life, exercise capacity and also provided 
strong evidence for reverse remodelling, resulting in reductions in both HF hospitalizations 
and all-cause morbidity and mortality in patients treated with CRT.3–7 Therefore, it is not 
surprisingly that CRT has been one of the most important breakthroughs in the treatment of 
HF and opened the door for implantable electrical therapy devices for HF patients. However, 
due to the results of these clinical trials indication for CRT devices have changing over the 
years. With every new release of the guidelines the target population is narrowed in order to 
select patients who really benefit from resynchronization therapy.8,9 According to the latest 
ESC guidelines from 2016, CRT is now indicated for patients with LV systolic dysfunction 
(left ventricular ejection fraction (LVEF) < 35%), QRS duration ≥ 130 ms and New York 
Heart Association (NYHA) functional class II or IV despite optimal medical therapy.9 
Unfortunately, a considerable amount of patients who are eligible according to recent 
guidelines, do not benefit substantially from CRT. In recent years, the proportion of patients 




The Concept of Dyssynchrony and Mechanism of Action of Cardiac 
Resynchronization Therapy 
In heart failure patients, conduction defects due to left bundle branch block (LBBB) or slow 
intra-myocardial conduction are common and result in regionally delayed electrical 
activation. An abnormal electrical activation pattern, so-called electrical dyssynchrony, has 
emerged as an important mechanisms contributing to the LV mechanical dyssynchrony, and 
appears to play a major role in the pathophysiology of HF.10 This dyssynchronous electrical 
activation of the complex myocardial fibre architecture in the LV additionally reduces LV 
contraction and decreases cardiac output, which further deteriorates cardiac function. 
Atrioventricular and interventricular electrical dyssynchrony reduces already impaired 
cardiac function. Intraventricular dyssynchrony results in temporal delay in electrical 
activation of one region of LV vs. another. LBBB, one of the well described intraventricular 
conduction delay in patients with HF, causes a dyssynchronous electrical activation across 
the LV, which leads to abnormal LV mechanical activation, with the earliest myocardial 
shortening in the septum and latest myocardial shortening in the lateral wall of  LV.11,12 
Because myocardial pumping efficiency is already compromised in HF patients, this 
electrical and mechanical dyssynchrony greatly reduces the efficiency of the ventricular 
pumping action, further exacerbating the negative hemodynamic consequences of HF. 
Biventricular pacing can modify the electrical activation patterns of the ventricles and result 
in improvements in both intraventricular and interventricular synchrony, in turn leading to 
an improvement in overall hemodynamic function (Figure 1). The mechanism of action by 
which CRT exerts its beneficial effect is based on pacing both the left and right ventricles 
simultaneously, thereby recoordinating the electrical and mechanical activation and 
consequently pumping action of the two ventricles. Biventricular pacing results in the 
generation of two ventricular activation wavefronts, which result in a more normal pattern 
of ventricular activation. LV contraction is more efficient and stroke volume is improved, 
without an increase in myocardial oxygen consumption by the heart,13 and both mitral 
regurgitation and myocardial diastolic dysfunction are often decreased.14–16 The mechanism 
by which CRT is thought to improve outcome is via decreased wall stress due to this reversed 
remodelling. A successful CRT results not only in a resynchronization of myocardial 




efficiency is increased and the amount of work the heart must do to maintain healthy blood 
circulation is reduced.11,17  
 
 
Figure 1. Summary of effect of cardiac resynchronization therapy in dyssynchronous heart 
failure.  
Biventricular pacing results in more synchronous electrical and mechanical activation of left 
ventricle (LV) and more homogeneous myocardial workload distribution within LV walls. Cardiac 
resynchronization therapy (CRT) restores also molecular and cellular changes in the 
dyssynchronous failing hearts. Consequently, all these changes caused by CRT lead to LV reverse 
remodelling with functional improvement in systolic function and the better long-term survival. After 
= after CRT; AVC = aortic valve closure; before = before CRT; ICD = implantable cardioverter-
defibrillator; lat = lateral wall; MVC = mitral valve closure; sep = septum; SR = sarcoplasmic 
reticulum; 4ch = 4 chamber view. 
 
Biventricular pacing also restores some molecular and cellular changes in the 




abnormalities of dyssynchronous heart, including more homogeneous activation of stress 
kinases and a reduction of cell apoptosis. These biochemical changes are associated with 
electrophysiologic changes.20,21 CRT restores ion channel remodelling and abnormal 
calcium homeostasis by restoring normal activity of sarcoplasmic reticulum Ca2+ adenosine 
triphosphatase.22 Additionally, CRT abbreviates action potential duration in the lateral LV, 
and reduces the number of early afterdepolarizations.20  
Role of Dyssynchrony Parameters in Predicting Response to Cardiac 
Resynchronization Therapy 
There are multiple factors that may influence the response to CRT. Most of the studies have 
focused only on parameters of mechanical dyssynchrony for predicting CRT response. 
Different parameters of mechanical dyssynchrony and disscordination, derived by different 
strain imaging techniques, based on echocardiography or CMR, are capable of detecting 
dyssynchronous mechanical activation. However, echocardiographic parameters of 
mechanical dyssynchrony failed to predict CRT response in a large multicentre study.23   
The response to CRT may be related to different parameters; also ECG parameters of 
conduction anomalies and electrical dyssynchrony can affect CRT response. CRT is merely 
electrical therapy which improves LV mechanical dyssynchrony by changing the sequence 
of electrical activation and restoring electrical synchrony.21,24 Therefore, ECG parameters of 
conduction anomalies and electrical dyssynchrony play an evolving and important role in 
understanding the mechanism of CRT response. Recent studies implicated that simple 
parameters from standard 12-lead ECG are important determinants of outcome after CRT 
(PR interval, QRS duration, axis, QT interval);25–28 however similar results were also found 
by analysing more complex ECG parameters (QRS morphology, intrinsicoid deflection ID 
- the time from the earliest onset of the QRS complex to the point where the longest, steepest, 
downward movement is inscribed at or after the peak of the R wave, LVAT- left ventricular 
activation time, difference between baseline and post-implant and  QRS duration).25,29–32  
Most of previous studies of analysing association between ECG variables and response to 
CRT, focused on definition of response, defined by echocardiographic improvement after 




volumes (ESV) ≥ 15%. It is known, that certain amount of patients, referred as “super-
responders”, may derive a significant improvement and extensive LV reverse remodelling 
with near normalization of LV volumes and function.33,34 However, studies analysing the 
relationship between ECG parameters and super-response to CRT are limited.  
Reverse Remodelling with Cardiac Resynchronisation Therapy 
CRT has shown a profound effect on reverse mechanical remodelling as well as on reverse 
electrical remodelling (ER).27 Several studies demonstrate the beneficial effects of CRT on 
LV mechanical remodelling, described by progressive improvement in ventricular structure 
and function.14,35  CRT does not only induce mechanical recovery of the heart, but also 
ameliorate conduction abnormalities. However, interdependence between electrical and 
mechanical remodelling and time course of electrical remodelling have not been fully 
investigated. Recent studies have focus merely on reverse mechanical remodelling. CRT 
induces sustained mechanical reverse remodelling with the most marked effects occurring 
within the first 9 months,36 whereas time course of ER has not yet been studied. As CRT is 
primarily electrical stimulation, we assume that reverse ER is reached before mechanical 
remodelling. According to the literature, data on relationship between electrical and 
mechanical remodelling are scant and contradictory. Some authors suggest that reversal ER 
should be related to LV structural remodelling,27,31 while others oppose this relationship.37,38 
Parameters that define mechanical remodelling are well known; these are LVEF and 
dimension of the LV (either diameter or volumes).24,27,39  On the other hand, parameters of 
ER have not been uniformly defined. Reverse ER after CRT might be associated with both 
depolarization and repolarization parameters. Some authors defined ER as a difference 
between baseline and post-implant pacing QRS duration40,41 whereas other used a difference 
between native QRS duration.31 Nevertheless, diverse criteria for electrical remodelling 
might account for different views about relationship between electrical and mechanical 
remodelling. The narrowing of paced QRS complex induced by biventricular pacing has 
been thoroughly studied.40 However, studies regarding ER of native conduction after CRT 
are scarce, yielding controversial results.31,37 Furthermore, only few data exists about a 
possible prognostic relationship of ER of native conduction with clinical outcome.42 Also, 




about the increase of dispersion of repolarization after CRT and potentially its proarrhytmic 
effect.43,44 On the other hand, some studies found amelioration of repolarization 
heterogeneity after CRT.27 In previous studies, high-resolution parameters of repolarization 
heterogeneity were primarily used as a predictive factor of ventricular tachyarrhytmias (VTs) 
after CRT.45,46 Only one study determined the effect of CRT on high-resolution parameters 
of repolarization heterogeneity.47 This study involved only a small number of patients and 
examined only acute changes of these parameters compared with different pacing modes.  
However, in the literature there are limiting data of analysis of ER from native or intrinsic 
ECG recording. There is also lack of data on comprehensive analysis of effect of CRT on 







The aim of this doctoral thesis was to evaluate the value of different ECG parameters in heart 
failure patients treated with CRT and to assess the relationship between electrical and 
mechanical reverse remodelling after CRT.  
The thesis is divided into three studies that are composed to form three related, but 
independent parts describing new understanding of ER in patients with CRT: 
 
I. The association of electrocardiographic parameters from 12-leads ECG and 
response to CRT 
The first study analyses the different pre-implant and immediate post-implant ECG 
parameters in patients undergoing CRT. The purpose of the study was to evaluate the 
association of baseline ECG parameters and dramatic response to CRT (super-response) at 
mid-term follow up.  
 
II. The effect of CRT on ventricular repolarization parameters and their 
relation to ventricular tachyarrhythmias  
The second study describes the effect of CRT on ventricular repolarization analysed from 
high-resolution Holter recording over 12 months after implantation and analyses the 
relationship between repolarization changes and occurrences of VTs in the observed period. 
 
III. Time course and relationship between electrical and mechanical reverse 
remodelling after CRT  
The third study considers the interactions between electrical and mechanical reverse 
remodelling after CRT. The aim of the study was to assess the time course of ER of native 
conduction and mechanical remodelling after CRT and to evaluate the impact of ER on 
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STUDY DESIGN, PARTICIPANTS AND METHODS 
STUDY POPULATION 
We enrolled heart failure patients referred to Department of Cardiology, University Medical 
Centre Ljubljana for CRT implantation. All patients were in accordance to contemporary 
recommendations for CRT (QRS width ≥ 120 ms, NYHA functional class II–IV symptoms 
refractory to optimal medical therapy, LVEF ≤ 35%).8 Exclusion criteria were pacemaker 
dependency, upgrading from right ventricular pacing to CRT (history of previous pacemaker 
dependence), atrial fibrillation/flutter, or any other non-sinus cardiac rhythm. Ischaemic 
aetiology was based on the angiographically proven >70% stenosis of at least one major 
epicardial coronary artery or documented myocardial infarction. All patients had routine pre-
implant and post-implant examinations according to the implant and follow-up 
recommendations and management of CRT patients of American and European society of 
cardiology.48 Patients were excluded from the analysis in case of device malfunction, lead 
dislodgement, less than 90% of biventricular pacing or inadequate echocardiographic image 
or ECG quality for analysis. 
STUDY DESIGN 
The study was approved by The National Medical Ethics Committee (Nb.: 21p/04/14). 
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I. The Association of Electrocardiographic Parameters from 12-Leads ECG and 
Response to Cardiac Resynchronization Therapy 
The study population was selected from a local clinical research database, which included 
245 consecutive patients implanted with a CRT device between February 2008 and 
November 2012. Flow chart of study design is presented on Figure 2. Inclusion criteria 
required that patients were in accordance to contemporary recommendations for CRT,49 had 
sinus rhythm and were not subject to CRT up-grade. Adequate follow-up with complete 
clinical assessment, ECG, and echocardiography suitable for this study was available in 101 
patients. After identification of super-responders group, remaining consecutive patients were 
used as control group. 
 
 
Figure 2. Flow chart of study design of association of electrocardiographic parameters and 
response to cardiac resynchronization therapy.  
 
STUDY DESIGN, PARTICIPANTS AND METHODS 
33 
 
II. The Effect of Cardiac Resynchronization Therapy on Ventricular Repolarization 
Parameters and their Relation to Ventricular Tachyarrhythmias  
In this prospective study, we included 69 HF patients referred to our hospital for cardiac 
resynchronization therapy with defibrillator (CRT-D) implantation between April 2012 and 
April 2015. Patients with severe concomitant comorbidities other than cardiac disease with 
a higher likelihood of death during first year after CRT implantation were excluded. Clinical 
and laboratory examinations, medical therapy, electrocardiographic, and echocardiographic 
parameters were recorded before CRT implantation. During follow-up at 1, 3, 6, 9 and 12-
month after CRT implantation clinical and electrocardiographic assessment were performed. 
Echocardiographic evaluation was performed 12 month after CRT implantation.  Patients 
were follow-up for 12 months after implantation of the CRT for VTs. Flow chart of study 




Figure 3. Flow chart of study design of effect of cardiac resynchronization therapy on ventricular 
repolarization parameters and their relation to ventricular tachyarrhythmias.   
20 min hrECG = 20 minutes high-resolution ECG recording. 
III. Time Course and Relationship between Electrical and Mechanical Reverse 
Remodelling after Cardiac Resynchronization Therapy  
In this prospective study, we included 62 HF patients referred to our hospital for CRT-D 
implantation between April 2012 and October 2014. All patients 
met contemporary guidelines for CRT-D implantation,8 had sinus rhythm and were not 
subject to CRT up-grade. Clinical and laboratory examinations, medical therapy, 12-leads 
ECG, and echocardiograms were recorded before CRT implantation. During follow-up at 1, 
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3, 6, 9 and 12-month after CRT implantation clinical, electrocardiographic and 
echocardiographic assessment were performed. Than after 12 months, patients were 
regularly followed-up every 6 months until February 2016 for HF hospitalization, 




Figure 4. Flow chart of study design of time course and relationship between electrical and 
mechanical reverse remodelling after cardiac resynchronization therapy.   
METHODS 
Device Implantation and Programming 
All patients underwent CRT implantation using standard techniques under local anaesthesia. 
Leads were positioned in the right atrium, the right ventricular apex or mid-septum and in a 
side branch of the coronary sinus, preferably in the posterolateral vein.  Patients received 
pulse generators from either Medtronic, Sorin Group or Biotronic and were programmed in 
the DDD(R) mode. For each patient, atrioventricular (AV) delay and interventricular (VV) 
delay optimization were performed after implantation. Additional reprogramming of CRT 
devices during follow-up occurred rarely and was typically performed only in the case of 
non-response. Selection of a specific type of device (biventricular pacemaker alone or 
combined with defibrillator) were based on valid guidelines and clinical history.  
STUDY DESIGN, PARTICIPANTS AND METHODS 
35 
 
Devices were programed with two tachycardia detection zone: ventricular tachycardia zone 
with at least 167 bpm and ventricular fibrillation (VF) zone with at least 200 bpm. Within 
above-mentioned zones, there were some individual device programming according to a 
patient’s profile in aetiology and type of indication. In ventricular tachycardia zone, first 
therapy was programmed to antitachycardia pacing (ATP), followed by high-voltage shock 
therapy, if ATP was unsuccessful; whereas VF was treated only with maximal energy 
shocks.   
Echocardiography Methods 
Transthoracic two-dimensional echocardiography was performed at least at baseline and at 
follow-up visit 12 months after device implantation. For study analysing time course and 
relationship between electrical and mechanical remodelling additional echocardiographic 
measurements were acquired 1, 3, 6, 9 months after implantation. All echocardiographic 
recordings were acquired while the biventricular pacing was active and were made on Vivid 
Systems ultrasound equipment. Standard images were examined by two cardiologists 
blinded to the study outcomes. Left ventricular end-diastolic volume (LVEDV), LV end-
systolic volume (LVESV), and LVEF were quantified using manual planimetry of two and 
four-chamber views and Simpson’s technique.50 
Electrocardiogram Recordings and Measurements 
Resting supine 12-lead ECGs (25 mm/s, 10 mm/mV) and 20-minutes high resolution Holter 
ECG were recorded before, immediately after CRT implantation and than at 1, 3, 6, 9 and 
12-month after CRT-D implantation. Baseline ECG was recorded within 1 week before CRT 
implantation. At follow-up we recorded ECGs during paced rhythm and during native 
rhythm; therefore CRT was temporarily reprogrammed to VVI 40 bpm to allow native 
conduction and after 5 minutes of native rhythm ECGs were recorded.  
 12-leads ECG 
We will analyse different depolarization and repolarization parameters from 12-lead ECG: 
PR interval, QRS morphology and duration, QRS axis, QT interval, heart rate-corrected QT 
interval (QTc) (Bazett`s formula) and intrinsicoid deflection (ID). The heart rate, axis, PR 
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and QT intervals were measured automatically by the machine built-in algorithm and 
verified by cardiologist. The frontal QRS axis was defined as follows: normal axis (-30° to 
90°), left axis (−90° to −30°), right inferior axis (90° to 180°) and right superior axis (180° 
to -90°). LBBB was defined using conventional criteria, namely QRS width ≥ 120 ms, QS 
or rS in lead V1, and a monophasic R wave with no Q waves in leads V6 and I.51 We further 
subdivided the LBBB into two groups according to the presence or absence of mid-QRS 
notching or slurring in at least two of the leads V1, V2, V5, V6, I, aVL. Whereas right bundle 
branch block (RBBB) was defined as rsr´, rsR´, or rSR´ in leads V1 or V2 and S wave of 
greater duration than R wave or greater than 40 ms in leads I and V6. Intraventricular 
conduction delay was diagnosed as QRS morphology that did not fit the criteria for RBBB 
or LBBB.  
All measurements of QRS duration and ID were made manually with the use of digital 
callipers at 400% magnification calibrated for paper speed 25 mm/s (Figure 5). The width 
of native QRS duration was measured from 12-leads ECG in the lead V2. The decision for 
using lead V2 was based on the previous results, which found right precordial lead (V1 or 
V2) as the most reliable lead for the actual QRS recording.52 We defined relative QRS 
shortening as the difference between baseline QRS duration and post-implant QRS duration 
divided by baseline QRS duration (
𝑝𝑜𝑠𝑡𝑖𝑚𝑝𝑙𝑎𝑛𝑡 𝑄𝑅𝑆−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑄𝑅𝑆
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑄𝑅𝑆
) expressed in percent. As 
negative value of relative change of QRS duration represents shortening of QRS duration, 
we used relative QRS shortening for negative relative changes. ID was measured in I and 
V1, defined as time from the onset of the QRS complex to the point where longest, steepest, 
downward movement is inscribed (maximum deflection toward the baseline) at or after the 
peak of the R wave in the lead of interest, and its derivative, time to ID in lead I - time to ID 
in lead V1.28 
Manually measured ECG parameters from 12-leads ECGs were analysed by two 
independent electrophysiologists blinded to the study outcome. If a discrepancy was present, 
the ECG measurements were reviewed again by the same analysts together to reach a 
consensus. 
 




Figure 5. Measurements of QRS duration and time to intrinsicoid deflection onset from a 12-lead 
ECG recording.  
A: 12-lead electrocardiogram before CRT implantation of a patient from our study population.  
B: Intrinsicoid deflection (ID) was measured with a 400% magnification from the lead I.  
C: Measurement of QRS duration from the lead V2 at the same magnification.  
 
 20-minutes high resolution Holter ECG 
The high-resolution (1000 Hz) Holter ECG recording was performed using SpiderView 
digital Holter recorder (ELA Medical, SORIN Group, Paris, France). The electrodes were 
placed in a pseudo-orthogonal X, Y, and Z lead configuration. All 20-min Holter recordings 
were performed at rest in the morning in our pacemaker outpatient clinic. To avoid excess 
daytime interference during recordings patients were in supine position in an isolated 
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environment (room with dim light). The ECGs were manually review and corrected for 
artefacts and templates adjusted if necessary.  
The method for measuring T-wave amplitude variability (TAV) has been previously 
described.45,46 Briefly, TAV was measured using SyneTVar 3.10b software (ELA Medical, 
SORIN Group, Paris, France) based on the vector magnitude (𝑉𝑀 = √𝑋2 + 𝑌2 + 𝑍2). The 
amount of variability was determined by the variance of the average amplitude across T 
wave segments in a selected cluster. The square root of this value was reported as TAV, 
expressed in microvolts (μV). Three different filters were applied and clusters were excluded 
from analysis in case of ventricular or atrial premature beat, high RR interval variability 
(heart rate varies > 20% around its mean), and noise level exceeding 10 mV. In our analysis, 
a cluster of 60 consecutive stable sinus beats was used (Figure 6). TAV was computed on 
10 consecutive 50 ms T-wave segments (T1–T10) following QRS offset (defined as QRS 
onset +150 ms, as previous described).46 The median TAV index was obtained by calculating 
the statistical median of all valid clusters of median TAV values in all segments (T1-T10) 
and max TAV as the maximum TAV value from T1 to T10 of all valid clusters.  
 
 
Figure 6. Scheme of the measurement of T-wave amplitude variability.  
T-wave amplitude variability (TAV) was computed on 10 consecutive 50 ms T-wave segments (T1–
T10) following QRS offset, from a cluster of 60 consecutive stable sinus beats. 
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Other repolarization analysis was performed with automatic QT analysis software (ELA 
Medical, SORIN Group), which calculates the mean QT values over 30-second periods over 
20-minutes recording. Software automatically measured the mean QT apex interval (QTa: 
time between the onset of QRS and the apex (peak) of the T wave) and QT end interval 
(QTe: time between the onset of QRS and the end of the T wave). All values were corrected 
for heart rate according to the Bazett`s formula (QTac, QTec). The peak of the T wave was 
determined using the parabola methods, which consists of finding the parabola best suited 
to the peak of the T wave. The end of the T wave is defined by the point of the intersection 
between the maximum decreasing tangent and the isoelectric line (Figure 7). If the 
negative/biphasic T waves were presented, the QTa was measured to the nadir of the T wave. 
In the case, a U wave was followed T wave, only the T wave was considered for 
measurement. The onset of the QRS complex and the peak and the end of the T wave were 
manually checked for accuracy and validated. Also, parameters of dispersion of 
repolarization were defined:  QTa dispersion (QTa disp) and QTd dispersion (QTe disp). 
Additionally, Tpeak to Tend interval (TpTe) and TpTe/QT ratio was measured. TpTe was 
defined as the interval from the peak (apex) of the T wave to the end of the T wave.  




Figure 7. Scheme of determination of QTa and QTe.  
The peak of the T wave is defined as a maximum of the fitted parabola. The end of the T wave is the 
point of intersection between the tangent drawn to the maximum of the T wave deflection and 
isoelectric line. 
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Definition of Electrical and Mechanical Remodelling 
An absolute decrease in the native pre-implant QRS duration ≥10 ms was defined as 
significant ER.42 Decrease in LVESV ≥ 15% 12 months after CRT was defined as standard 
echocardiographic response,53 termed mechanical remodelling. However, patients whose 
absolute LVESV after CRT decreased ≥ 30% were classified as super-responders.34 
Evaluation of remodelling was performed during first 12 months after CRT implantation. 
Follow-up, Ventricular Tachyarrhythmia and Clinical Outcome 
After CRT implantation regular outpatient visits were scheduled for all patients. In the first 
year after implantation, visits were scheduled at 1, 3, 6, 9 and 12 months, than regularly 
every 6 months. Additional follow-up was made in the case of a device shock or new 
symptoms onset of heart failure. Ventricular tachyarrhythmia episodes (VTs) were classified 
as sustained ventricular tachycardia (VT) with appropriate ICD therapy (ATP/shock) or VF. 
Two independent electrophysiologists blinded to the study outcome validated VTs and 
appropriateness of ICD therapy. Inappropriate therapy and episodes of non-sustained 
ventricular tachycardias were excluded from our analysis.  
A primary end point was combined, including HF hospitalization, cardiovascular death and 
cardiac transplantation. For combined end points, only the first event for each patient was 
included in the analysis. Heart failure hospitalization was defined as an admission to the 
hospital due to patient`s signs and symptoms of decompensated HF requiring treatment with 
intravenous medical therapy. 
Statistical Analysis  
The Kolmogorov–Smirnov test was used to verify normal distribution. Normally distributed 
continuous variables were expressed as means and standard deviations. In non-normal 
distributed continuous variables, data were expressed as median together with the 25th and 
75th percentiles (inter-quartile range). Categorical data were summarized as frequencies and 
percentages. For comparison of continuous variables paired and unpaired Student`s t-test 
was used for normally distributed variables and the Wilcoxon matched-pair test or the Mann-
Whitney U test for non-normally distributed variables. One-way repeated measures analysis 
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of variance (ANOVA) was used to analyse changes over time within group. Bonferroni 
correction was applied due to multiple comparisons. In case the variables were non-normally 
distributed, changes over time within a group were analysed by the Friedman test. If the 
Friedman test was significant, comparisons between pairs of states were made using the 
Wilcoxon signed rank test with Bonferroni correction. The data for categorical variables 
were analysed using the Fisher`s exact test or Chi-square test.  
Univariate and multivariate logistic regression analysis were performed to identify variables 
independently associated with super-response. Based on Hosmer-Lemeshow guidelines, 
only variables with P < 0.2 in the univariate analysis were entered into a forward stepwise 
procedure.54 Multivariate logistic regression was performed to obtain the best-fit model 
using the most important independent variable influencing super-response as the dependent 
variable. Because QRS duration and ID variables were strongly related, these variables were 
included separately in multivariate analysis. For this purpose, different multivariate logistic 
regression models were constructed. The odds ratio (OR) and 95% confidence interval (CI) 
were reported. The optimal value of QRS duration variables to predict super-response of 
CRT was determined by receiver-operating characteristic (ROC) curve analysis. 
Kaplan-Meier curves were constructed to compare survival free from the combined end 
point between the groups and the log-rank test was used to determine 
significance. Additionally, univariate Cox proportional hazards models were performed to 
determine potential predictors of the combined end point. Multivariate analysis was not done 
due to the limited number of events. 
For all test, a two-tailed P value < 0.05 was considered statistically significant. Data were 








I. The Association of Electrocardiographic Parameters from 12-leads 
ECG and Response to Cardiac Resynchronization Therapy 
Study Population Characteristics 
The study population consisted of 101 patients with a mean age of 63.2 ± 10.9 years, 
predominantly male (66 patients; 65.2%) with non-ischaemic cardiomyopathy (37 patients; 
36.6%). Most of the patients were in NYHA functional class III (77; 76.2%). Median LVEF 
was 25.0% (20.0-30.0). Most of the patients had LV lead position in postero-lateral vein (81 
patients, 80.2%). Other baseline clinical characteristics, echocardiographic and ECG 
characteristics are presented in Table 1. All patients received optimal medical therapy, if 
tolerated. Angiotensin converting enzyme inhibitors or angiotensin II receptor blocker were 
taken by 99 patients (98%), β-blockers 100 patients (99%), spironolactone 90 patients 
(89.1%) and diuretics 70 patients (69.3%).   
Clinical, Echocardiographic and Electrocardiographic Characteristics of Super-
responders 
After 12 months of biventricular pacing, 32 patients (31.7%) fulfilled the echocardiographic 
criteria of super-response (a relative reduction in LVESV ≥ 30%). A reduction in LVESV 
of 15–29% was reported in 15 patients (14.9%), whereas 54 patients (53.5%) did not show 








Figure 8. Percentage assignment 
of the study population to response 
classes.  
∆ESV ≥ 30% = super-responders; 
∆ESV 15-29% = responders;  




A comparison of clinical and baseline echocardiographic parameters between super-
responders and non-super-responders is summarized in Table 1. Super-responders had 
significantly lower preimplant proBNP, whereas there were no differences in other clinical 
characteristics, heart failure therapy and baseline echocardiographic parameters. In super-
responders post-implant ESV was 94.2 ± 34.7 ml and EF was 46.3 ± 7.4 %, whereas in non-
super-responder group ESV was 194.1 ± 70.1 ml and EF was 28.0 ± 8.1%. There was no 
statistically significant difference in LV lead position (P = 0.127); in both group LV lead 
position was predominantly located in the postero-lateral vein (29 patients [90.6%] in super-
responder group; 52 patients [75.4%] in non-super-responder group). Additionally, the 
number of patients with CRT-D and cardiac resynchronization therapy pacemaker (CRT-P) 
were comparable in both groups (super-responders: 29 patients [91%] vs. non-super-
responders: 65 patients [94%]; P = 0.676). 
There were no statistically significant differences in baseline heart rate, PR interval, QRS 
duration, QRS axis and QTc interval when super-responder group was compared with non-
super-responder group (Table 1). A detailed analysis of QRS morphology did not reveal 
significant difference between both groups. Not only conventional LBBB morphology but 
also LBBB with mid-QRS notching was similar between group of super-responders and non-
super-responders (25 patients (78.1%) vs. 42 patients (60.9%); P = 0.088). There was 
borderline significant association between super-responders in ID in lead I minus lead V1 
(P = 0.050), whereas other ID measurements were not significantly different between the 
two groups (Table 1).  Absolute post-implant paced QRS duration was shorter in super-
responder group (148 ± 22 ms vs. 162 ± 28 ms; P = 0.010). Additionally, only in super-




from 167 ± 26 ms to 148 ± 22 ms; P = 0.010 vs. non-super-responders: from 165 ± 27 ms to 
162 ± 28 ms; P = 0.536) (Figure 9). Relative shortening of QRS complex was also calculated 
and was significantly higher in super-responders (12.1% [6.8 - 22.2] vs. 1.7% [(-11.9) to 
11.8]; P = 0.005).  
 
Table 1. Baseline characteristics of all patients and comparison of group of super-responders and 
non-super-responders. 
 All (n = 101) Super-responders 
(n=  32) 
Non-super-
responders 
( n = 69) 
P-value 
Clinical characteristics 
Age (years) 63.2 ± 10.9 62.3 ± 11.1 63.6 ± 11.3 0.596 
Male (%) 66 (65.2) 19 (59.4) 47 (68.1) 0.390 
Ischemic cardiomyopathy (%) 37 (36.6) 10 (31.3) 27 (39.1) 0.444 
NYHA class I/II/III/IV 0/14/77/10 0/8/21/3 0/6/56/7 0.101 
6-MWT (m) 351 ± 109 362 ± 113 347 ± 109 0.557 
proBNP (ng/L) 1649 (795-3186) 909 (602-1448) 2267 (1335-4032) <0.001 
Diabetes mellitus (%) 24 (23.8) 10 (31.3) 14 (20.3) 0.229 
Serum creatinine (mmol/L) 88 (75-109) 88 (75-103) 88 (75-113) 0.597 
Echocardiographic parameters 
LVEF (%) 25 (20-30) 26 (21-31) 25 (20-30) 0.579 
LVESV (mL) 193 ± 65 182 ± 56 198 ± 69 0.245 
LVEDV (mL) 260 ± 75 247 ± 75 267 ± 78 0.211 
ECG parameters 
Heart rate (bpm) 73 ± 15 73 ± 12 73 ± 16 0.909 
QRS duration (ms) 166 ± 26 167 ± 26 165 ± 27 0.631 
QRS morphology     
     LBBB conventional (%) 70 (69.3) 25 (78.1) 45 (65.2) 0.191 
     RBBB (%) 1 (1) 0 (0) 1 (1.4) 1.000 
     IVC (%) 29 (28.7) 7 (21.9) 22 (31.9) 0.301 
PR interval (ms) 184 ± 31 185 ± 22 183 ± 34 0.671 
QTc (ms) 493 ± 32 497 ± 25 492 ± 35 0.458 
Axis    0.218 
     Normal (%) 47 (46.5) 19 (59.4) 28 (40.6)  
     Left (%) 47 (46.5) 12 (37.5) 35 (50.7)  
     Right inferior (%) 3 (3) 1 (3.1) 2 (2.9)  
     Right superior (%) 4 (4) 0 (0) 4 (5.8)  
Intrinsicoid deflection  (ms)     
     Lead V1 19 (0-24) 15 (0-24) 20 (10-24) 0.323 
     Lead I 121 (86-136) 128 (112-141) 119 (81-136) 0.141 
     Lead I-lead V1 105 (81-126) 117 (87-131) 99 (69-118) 0.050 
NYHA class = New York Heart Association class; 6-MWT = 6-min walking distance test; BNP = 
brain natriuretic peptide; LVEF = left ventricular ejection fraction; LVESV = left ventricular end 
systolic volume; LVEDV = left ventricular end diastolic volume; LBBB = left bundle branch block; 





Figure 9. QRS duration before and after 
cardiac resynchronization therapy in 
group of super-responders and group of 
non-super-responders.  


















Variables Associated with Super-response to CRT 
To investigate whether the ECG variables were associated with super-response to CRT, we 
performed univariate and multivariate logistic regression analysis. In the univariate analysis, 
variables that correlated with super-response to CRT were NYHA class, post-implant QRS 
duration and relative shortening of QRS complex (Table 2). Other clinically relevant 
variables (aetiology, baseline LVEF and LV volumes, QRS morphology, baseline QRS 
duration, ID parameters) were non-significant in univariate analyses. A multivariate logistic 
regression model was constructed adjusting for NYHA class, intermediate axis, LBBB with 
mid-QRS notching, post-implant QRS duration, relative QRS shortening and ID parameters 
(P <0.2 in the univariate analysis). Because QRS duration parameters and ID parameters had 
a strong correlation, these factors were separately assessed in multivariate analysis. In 
separate multivariate models, none of the ID parameters (ID I-V1 (per 10 ms): OR 1.09, 95% 
CI (1.08-1.10); P = 0.503 and ID I (per 10 ms): OR 1.06, 95% CI (1.05-1.07); P = 0.280) 
were significant after adjusting for NYHA class, intermediate axis, LBBB with mid-QRS 
notching. Post-implant QRS duration and NYHA class stayed significant after adjusting for 




independently related to super-response to CRT in multivariate model adjusting for NYHA 
class, intermediate axis and LBBB with mid-QRS notching (Table 2).  
 
Table 2. Univariate and multivariate logistic regression of factors associated with super-response 
to cardiac resynchronization therapy. 
Variable 
 
OR 95% CI P-value 
Univariate analysis 
Ischemic cardiomyopathy 1.41 0.58-3.44 0.445 
NYHA class II vs.III/IV 0.29 0.09-0.91 0.034 
LVEF (per 1%) 1.02 0.95-1.09 0.637 
LVESV (per 1 mL) 0.99 0.99-1.00 0.252 
LVEDV (per 1 mL) 0.99 0.99-1.00 0.210 
PR interval (per 10 ms) 1.03 1.02-1.05 0.710 
QTc (per 10 ms) 1.05 1.04-1.07 0.509 
Intermediate axis 0.47 0.20-1.10 0.081 
LBBB-notch 0.44 0.17-1.15 0.092 
Baseline QRS duration (per 10 ms) 1.04 1.03-1.06 0.627 
Post-implant QRS duration (per 10 ms) 0.79 0.77-0.80 0.012 
Relative QRS shortening (per 10%) 1.31 1.28-1.34 0.027 
ID I (per 10 ms) 1.12 1.10-1.13 0.111 
ID V1 (per 10 ms) 0.87 0.84-0.90 0.333 
ID I-V1 (per 10 ms) 1.12 1.10-1.13 0.082 
Multivariate analysis (model 1) 
NYHA class II vs.III/IV 0.29 0.08-0.98 0.047 
Intermediate axis 0.57 0.28-1.45 0.240 
LBBB-notch 0.41 0.14-1.16 0.093 
Post-implant QRS duration (per 10 ms) 0.76 0.75-0.77 0.009 
Multivariate analysis (model 1) 
NYHA class II vs.III/IV 0.30 0.88-1.00 0.057 
Intermediate axis 0.41 0.16-1.06 0.066 
LBBB-notch 0.68 0.23-1.97 0.470 
Relative QRS shortening (per 10%) 1.36 1.34-1.38 0.021 
OR = odds ratio; CI = confidence interval; NYHA class = New York Heart Association class; LVEF 
= left ventricular ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left 
ventricular end diastolic volume; LBBB = left bundle branch block; ID I= intrinsicoid deflection in 
lead I; ID V1= intrinsicoid deflection in lead V1; ID I-V1 = difference between intrinsicoid deflection 
in lead I and V1. 
 
To define the optimal cut-off value of QRS duration parameters to predict super-response of 
CRT, ROC curve analysis were performed. Figure 10 shows a ROC curve of relative QRS 
shortening to predict super-response (AUC = 0.68, 95% CI 0.56-0.79). The cut-off value of 
QRS shortening > 4.5% had a sensitivity of 81% and a specificity of 58%. Absolute post-




ROC curve analysis (AUC = 0.33, 95% CI 0.23-0.45), similar as baseline QRS duration 
(AUC = 0.51, 95% CI 0.39-0.63). 
 
Figure 10. ROC curve 
analysis for predicting 
super-response to cardiac 
resynchronization therapy.  
Small numbers next to the 
line indicate percent of 






II. The Effect of Cardiac Resynchronization Therapy on Ventricular 
Repolarization Parameters and their Relation to Ventricular 
Tachyarrhythmias  
Study Population  
In 5 of 69 patients included in the study, analysis of high-resolution ECG parameters could 
not be possible because of technical criteria for the methods (frequent occurrences of 
premature ventricular beats). Therefore, in the analysis we included 64 patients with a mean 
age of 63.9 ± 10.9 years. Most patients were men (47 patients; 73.4%), with non-ischaemic 
cardiomyopathy (41 patients; 64%) and in NYHA functional class III (47 patients; 73.4%). 
Baseline clinical, echocardiographic and ECG characteristics are presented in Table 3. All 
patients received optimal HF medical therapy. There were 9 patients (14.1%) with the history 
of sustain VT or VF before device implantation. The LV lead was implanted mainly in 
posterolateral vein (44 patients; 68.8%). 
Echocardiographic Response to CRT  
Response to CRT, predefined as a relative reduction in LVESV ≥15%, was observed in 33 
patients (51.6%). In responder group, there was significant improvement in 
echocardiographic parameters after 12 months of CRT (EDV:  216 ml [169-242] vs. 145 ml 
[105-180], P < 0.001; ESV: 151 ml [119-181] vs. 74 ml [48-113], P < 0.001; EF: 28% [24-
31] vs 49% [39-56], P < 0.001). Conversely, non-responder to CRT had no improvement or 
even significant worsening of echocardiographic parameters one year after implantation 
(EDV: 246 ml [200-330] vs. 268 ml 220-345], P = 0.013; ESV: 184 ml [150-241] vs. 202 
ml [157-265], P < 0.001; EF: 25% [23-31] vs. 24% [20-28], P = 0.055).  
Changes of Cardiac Repolarization within 1 Year after CRT Implantation 
No significant changes of heart rate during first 12 months after CRT implantation was 
detected (P = 0.054). There were significant changes in repolarization parameters of native 
conduction over 12 months after CRT implantation. Changes in repolarization parameters 




Table 3. Baseline characteristics of the study population. 
 All (n = 64) 
Clinical characteristics  
Age (years) 63.9 ± 10.9 
Male (%) 47 (73.4) 
Ischaemic cardiomyopathy (%) 23 (35.9) 
NYHA class I/II/III/IV 0/17/47/0 
proBNP (ng/L) 1687 (821-2915) 
PAF (%) 9 (14.1) 
Diabetes mellitus (%) 17 (26.6) 
eGFR, ml/min per 1.73 m2 71 ± 20 
Drugs  
   β-blockers (%) 59 (92.2) 
   ACE-i/ARB (%) 61 (95.3) 
   Spironolactone (%) 55 (85.9) 
   Diuretics (%) 41 (64.1) 
   Amiodarone (%) 9 (14.1) 
ECG parameters  
Heart rate (bpm) 63  ± 9 
QRS duration (ms) 185 (173-194) 
QRS morphology  
     LBBB (%) 44 (68.8) 
     RBBB (%) 2 (3.1) 
     IVC (%) 18 (28.1) 
Echocardiographic parameters  
LVEDV (mL) 230 (190-282) 
LVEDSV (mL) 167 (133-217) 
LVEF (%) 27 (23-31) 
NYHA class = New York Heart Association class; eGFR = estimated glomerular filtration rate; BNP 
=brain natriuretic peptide; PAF = paroxysmal atrial fibrillation; ACE-I = angiotensin-converting 
enzyme inhibitors; ARB = angiotensin II receptor blockers; LBBB = left bundle branch block; RBBB 
= right bundle branch block; IVC = intraventricular conduction delay; LVEF = left ventricular 
ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left ventricular end 
diastolic volume. 
 
Significant changes over time was observed in QTec (Figure 11.B), TpTe (Figure 11C), 
TpTe/QT ratio (Figure 11D) and dispersion of QTe (Table 4), whereas TAV values (Figure 
11A), QTa interval and its dispersion were unchanged over first year after CRT (Table 4). 
All repolarization parameters showed a similar pattern of changes during first 12 months 
after CRT implantation. In first months after CRT implantation increased repolarization 






Figure 11. Changes of repolarization parameters in the first year after initiation of cardiac 
resynchronization therapy.  
A. median TAV (Friedman test: P =0.42), B. QTec interval (one-way repeated measures ANOVA: 
P<0.001), C. TpTe (Friedman test: P<0.001) and D. TpTe/QT ratio (Friedman test: P < 0.001). If 
ANOVA/Friedman test yielded a P-value < 0.05, a post hoc comparison between study time was 
performed (P < 0.05, vs. baseline, indicated with * above bars). Values are presented as means with 
standard deviations on panel B, whereas on other panels values are presented as median and 
interquartile range.  
 
 
Table 4. Time-dependent changes of repolarization parameters after cardiac resynchronization 
terapy implantation. 



















378 ± 31 385 ± 28 383 ± 30 382 ± 27 380 ± 26 378 ± 28 0.179 
QTa disp 
(ms) 
14 (12-19) 16 (13-22) 19 (13-25) 16 (13-23) 17 (13-23) 17 (13-17) 0.054 
QTe disp 
(ms) 
14 (11-22) 18 (12-26)* 19 (14-25)* 17 (12-22) 18 (15-25)* 17 (14-26) 0.014 
*P < 0.05, vs. baseline, by one way repeated-measures ANOVA or Friedman test with post hoc 
analysis.  
 
In a separate analysis of responder and non-responder group, changes in repolarization 
parameters over time were more prominent and had diverse patterns of distribution in both 




with and those without echocardiographic response to CRT. However, increase of 
repolarization heterogeneity in the first month after CRT was detected in both group (Figure 
12). Significant changes in QTec (P < 0.001), TpTe (P < 0.001), TpTe/QT ratio (P < 0.001) 
and QTe dispersion (P = 0.024) were observed in non-responder during the follow-up period, 
evidenced by progressive increase of repolarization parameters at follow-ups compared with 
pre-implant value (Figure 12B, C, D). No significant differences over time were found in 
QTac and QT dispersion in non-responder group. 
  
 
Figure 12. Changes of repolarization parameters in the first year after initiation of cardiac 
resynchronization therapy in responder and non-responder group.  
A Median TAV, B. QTec interval, C. TpTe, D. TpTe/QT ratio. P < 0.05, indicated with * above 
connecting bars presented the difference between responder and non-responder. Values are 
presented as means with standard deviations on panel B, whereas on other panels values are 
presented as median and interquartile range. 
 
In responder group, significant differences of QTac (P = 0.005), QTec (P = 0.011), TpTe (P 
= 0.002) and TpTe/QT ratio (P = 0.004) were found over time (Figure 12). Despite 
significant prolongation of QTec at 1 month after CRT comparing pre-implant measurement 
(475 ± 30 ms vs. 499 ± 32 ms; P = 0.019), decrease of QTec was noted at 6, 9 and 12 month 




TpTe/QT ratio markedly increased 3 and 6 months after CRT implantation (Figure 12C,D), 
however, at later follow-up visits no significant changes were detected comparing the pre-
implant values. No significant temporal changes of median TAV were detected in both 
responder (P = 0.431) and non-responder group (P = 0.536) (Figure 12A). However, there 
was a trend for TAV to decrease over time in responder group and to increase in non-
responder group.  
Responder and non-responder group had similar pre-implant value of all repolarization 
parameters. Significant difference between groups in QTec was detected only at 9 and 12 
months follow-up visit (responder vs. non-responder: 9 month: 482 ± 29 ms vs. 502 ± 30 
ms, P = 0.032; 12 month: 483 ± 37 vs. 507 ± 35, P = 0.01) (Figure 12B). Median TAV in 
responder group was significant lower than in non-responder group at 6, 9 and 12-month 
follow-up (6 month: 23.3 (16.3-32.9) μV vs. 26.7 (22.0-38.8) μV, P = 0.043; 9 month: 21.5 
(20.2-30.9) μV vs. 26.3 (21.2-40.36) μV, P = 0.032; 12 month: 23.2 (20.5-26.8) μV vs. 28.4 
(23.9-44.5) μV, P = 0.029) (Figure 12A). However, TpTe and TpTe/QT ratio had differed 
between groups only at 12 months after CRT implantation (responders vs non-responders: 
TpTe: 99 (92-113) ms vs. 121 (90-147) ms; P = 0.05; TpTe/QT ratio: 0.207 (0.189-0.227) 
vs. 0.243 (0.196-0.273); P = 0.042) (Figure 12C, D).  However, the QTac values and max 
TAV were comparable between groups at follow-ups.  
Ventricular Arrhythmia within 1 Year after CRT Implantation 
Appropriate device therapy was documented in 10 patients (15.6%) within 1 year after CRT 
implantation. Of these patients, 7 experienced at least two VTs within first year. There were 
a total of 27 VTs, 25 were classified as VT and two were classified as VF. Shock therapies 
terminated 2 VF and 5 VT, whereas other VTs were successfully terminated with 
antitachycardia pacing. Distribution of patients with VTs during first year after CRT is 
presented in Figure 13. More than half of the patients (6 patients; 60%) had VTs within the 
first month after CRT implantation. Distribution of VTs with the highest occurrence in the 
first month corresponded with the highest repolarization heterogeneity in the same period. 
Both VF episodes were occurred in the first month after CRT in the same patient. All patients 




However, rate of VTs events during first 12 months after CRT was not significantly different 
between responder and non-responder group (6 of 31 (29%) non-responders vs. 4 of 33 
responders (12%); Fisher`s exact test P = 0.504; log-rank test P = 0.432). No significant 
difference between patients with and without VTs during 12 months was noticed in 
repolarization parameters before CRT implantation.  
 
 
Figure 13. Distribution of patients 
with ventricular tachyarrhythmias 
during first year after cardiac 














III. Time Course and Relationship between Electrical and Mechanical 
Reverse Remodelling after Cardiac Resynchronization Therapy 
Study Population Characteristics 
The study population included 62 patients with a mean age of 65.7 ± 10.3 years. Most 
patients were men, with non-ischaemic cardiomyopathy and in NYHA class III (48; 77.4%). 
All patients received optimal HF medical therapy. The LV lead was inserted mainly in 
posterolateral vein (45; 72.6%). All patients were in sinus rhythm at the time of implantation 
and during ECG recording at every follow-up. Other clinical, ECG and echocardiographic 
characteristics are reported in Table 5. 
Time Course and Relationship between Electrical and Mechanical Remodelling 
There were significant changes in ECG parameters of native conduction during 12 months 
of follow-up after CRT implantation. Changes in QRS duration from pre-implant and over 
12 months follow-up period are shown in Table 6. Significant shortening of QRS duration 
was already observed at 1 month after implantation and persisted during follow-up. The 
median shortening of QRS duration in the first month after CRT implant was 5.5 ms (0.0-
10.0). A significant change of repolarization ECG parameter from 12-lead ECG Holter 
recording during follow-up was noticed (Table 6); all follow-up values of QTc were 
significant higher compared to pre-implant QTc, with the greatest prolongation in the first 
month after CRT implantation. There was also significant difference in PR interval between 
measurements during follow-up, but significant prolongation of PR interval from the pre-
implant value was only observed after 9 months of CRT. No significant changes in QRS axis 
during follow-up were observed.   
Progressive LV structural remodelling was observed during 12 months of follow-up (Table 
6) with continuous reductions in LV volumes and improvement of LVEF (P <0.001, for all). 
However, significant echocardiographic changes compared to pre-implant measurements 





Table 5. Baseline characteristics of all patients and comparison between the group with electrical 
remodelling and the group without electrical remodelling. 
 All (n = 62) Electrical 
remodelling 
(n=  24) 
Without electrical 
remodelling 
( n = 38) 
P-value 
Clinical characteristics 
Age (years) 65.7 ± 10.3 64.6  ± 9.7 66.3  ± 10.7 0.524 
Male (%) 50 (80.6) 19 (79.2) 31 (81.6) 0.815 
Ischaemic cardiomyopathy (%) 25 (40.3) 6 (25.0) 19 (50.0) 0.051 
NYHA class I/II/III/IV 0/14/48/0 0/7/17/0 0/7/31/0 0.324 
6-MWT (m) 340 (323-472) 434 (335-484) 428 (323-460) 0.557 
proBNP (ng/L) 1659 (827-3384) 1040 (642-2104) 1909 (889-4217) 0.022 
PAF (%) 8 (12.9) 2 (8.3) 6 (15.8) 0.468 
Diabetes mellitus (%) 17 (27.4) 6 (25.0) 11 (28.9) 0.734 
eGFR, ml/min per 1.73 m2 68 ± 20 71 ± 21 66 ± 21 0.414 
Medical therapy 
   β-blockers (%) 57 (91.9) 23 (95.8) 34 (89.5) 0.640 
   ACE-i/ARB (%) 59 (95.2) 23 (95.8) 36 (94.7) 1.000 
   Spironolactone (%) 53 (85.5) 23 (95.8) 30  (78.9) 0.135 
   Diuretics (%) 44 (71) 17 (70.8) 27 (71.1) 0.985 
ECG parameters 
Heart rate (bpm) 69 ± 11 71 ± 12 70 ± 11 0.707 
PR interval (ms) 193 (172-222) 183 (168-200) 199 (173-230) 0.073 
QRS duration (ms) 185 (175-194) 190 (179-196) 180 (174-191) 0.113 
QRS morphology     
     LBBB (%) 40 (64.5) 19 (79.2) 21 (55.2) 0.055 
     RBBB (%) 3 (4.8) 1 (4.2) 2 (5.3) 1.000 
     IVC (%) 19 (30.6) 4 (16.7) 15 (39.5) 0.058 
QT (ms) 459 (437-488) 471 (442-488) 454 (436-483) 0.355 
QTc (ms) 484 (469-502) 488 (472-506) 479 (460-497) 0.250 
QRS axis (°) -27 (-55 to 29) -16 (-53 to 49) -32 (-57 to 19) 0.488 
Echocardiographic parameters 
LVEDV (mL) 231 (191-280) 218 (168-260) 237 (200-288) 0.148 
LVEDSV (mL) 167 (137-206) 156 (123-182) 173 (143-217) 0.140 
LVEF (%) 27 (24-31) 29 (25-31) 26 (24-31) 0.170 
NYHA class = New York Heart Association class; eGFR = estimated glomerular filtration rate ; 6-MWT = 6-
minute walking distance test; BNP = brain natriuretic peptide; PAF = paroxysmal atrial fibrillation; ACE-I 
= angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; LBBB = left bundle 
branch block; RBBB = right bundle branch block; IVC = intraventricular conduction delay; LVEF = left 
ventricular ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left ventricular end 
diastolic volume. 
 
In 24 patients (38.7%) ER was observed and 31 patients (50%) showed mechanical 
remodelling (Figure 14). More than half of the patients (14 patients; 58.3%) in the ER group 
showed ER one month after CRT. However, among echocardiographic responders 




Furthermore, 21 (33.9%) patients showed both ER and mechanical remodelling, 3 (4.8%) 
patients had only ER, and 10 (16.1%) patients had only mechanical remodelling. In addition, 
28 (45.2%) patients in the study population showed neither ER nor mechanical remodelling. 
 


















































QRS axis (°) -27  
(-55 to 29) 
-20  
(-40 to 27) 
-20  
(-45 to 29) 
-13  
(-44 to 22) 
-15  
(-47 to 32) 
-23  
(-43 to 28) 
0.695 
Echocardiographic parameters 


























LVEF (%) 27 (24-31) 29 (22-35) 31 (24-38) * 32 (25-40) * 32 (25-40)+ 32 (25-40) * <0.001 
LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = 
left ventricular end diastolic volume.   
The nonparametric repeated measures comparison between states was performed by the use of the 
Friedman test (P-value). The Wilcoxon signed rank test was used to compare pair of pre-implant 




Figure 14. Number of patients with 
remodelling after one year of biventricular 
pacing.  
Electrical remodelling: absolute decrease 
in the native pre-implant QRS duration ≥ 10 
ms. Mechanical remodelling: decrease in 







Patients with and without ER had similar baseline ECG and echocardiographic 
characteristics (Table 5). Group of patients with ER had lower baseline proBNP and had a 
trend toward more non-ischaemic cardiomyopathy, whereas other baseline characteristics 
were comparable. In both groups, LV lead was predominantly located in the posterolateral 
vein. Patients with ER had also shorter paced QRS duration after CRT compared with those 
without ER (162 ± 17 ms vs. 174 ± 20 ms; P = 0.034). Furthermore, mechanical remodelling 
was present more often among patients with ER compared to patients without ER (21 
patients (87.5%) vs. 10 patients (26.3%); P < 0.001). 
In patients with ER significant difference of native QRS durations between baseline and 
follow-up visits was noticed (P < 0.001). The reduction in QRS duration was already 
pronounced after one month of CRT (pre-implant vs. 1 month: 190 ms [179-196] vs. 180 ms 
[173-186]; P < 0.001) and persisted over follow-up. On the other hand, there were no 
changes in QRS duration during follow-ups in patients without ER was observed (P = 0.233). 
Significant differences in native QRS duration from baseline to successive follow-up visits 
were noticed between patients with and without ER (Figure 15A). In addition, in both group 
no difference in QRS axis was observed during follow-up. During 12 months PR interval 
did not change in patients with ER, whereas prolongation of PR interval was found in 
patients without ER. Significant prolongation of native QTc from pre-implant was noticed 
on every follow-up visits in patients without ER. However, in patients with ER, significant 
QTc prolongation was detected only at first month.  
One month after CRT implantation relative changes in ESV were similar in patients with ER 
and patients without ER (group with ER vs. group without ER: -6.7% [-11.7 to -0.2] vs.-
2.6% [-7.3 to 5.1]; P = 0.060) (Figure 15B). However, at later follow-up visits patients with 
ER demonstrated progressive LV reverse remodelling and significant difference in relative 
changes in ESV from pre-implant values were noticed compared with patients without ER. 
In addition, only in group with ER these signs of reverse mechanical remodelling were also 
accompanied by significant reductions in EDV and improvement in LVEF during the same 







Figure 15. Difference in native QRS duration (A) and in change in left ventricular end-systolic 
volume (B) from baseline to successive follow-up visits between patients with electrical 
remodelling and patients without electrical remodelling.  
The data were calculated as baseline value minus follow up value, therefore negative values present 
shortening of QRS complex or reduction of ESV at follow-up. The data were presented as median 
and inter-quartile range. P <0.05, indicated with * above connecting bars presented the difference 
between patients with electrical remodelling and patients without electrical remodelling. ER = 
patients with electrical remodelling; without ER = patients without electrical remodelling; ESV = 
end-systolic volume; mo = month. 
 
Electrical Remodelling and Clinical Outcome  
During a median follow-up of 27 months (18–37 months), 6 patients died (9.7%) and one 
(1.6%) patient had cardiac transplantation. There were 12 (19.4%) HF hospitalizations; 3 
patients who died and 1 patient who underwent cardiac transplantation were also 
hospitalized due to deterioration of HF. Specifically, the combined end point was observed 
in 15 (24.2%) patients. Compared with patients without ER, a superior survival free from 
the combined end point was observed among patients with ER (chi-squared = 4.85, log-rank 
P = 0.028) (Figure 16).  
To investigate whether ER predicts HF hospitalization, cardiovascular death and cardiac 
transplantation Cox proportional hazards regression analysis was performed. In the 
univariate analysis, variables that were significantly related to the combined end point were 
proBNP (log-transformed proBNP), LBBB, ER, echocardiographic response and pre-




fold decrease in the risk of HF hospitalization, cardiovascular death and cardiac 
transplantation (hazard ratio [HR] 0.22; 95% CI (0.05-0.98); P = 0.047). 
 
Figure 16. Kaplan–Meier curves 
comparing the survival free of 
combined endpoint (heart failure 
hospitalization, cardiac death and 
cardiac transplantation) between 
the patients with electrical 
remodelling and patients without 
electrical remodelling. 
ER = patients with electrical 
remodelling;  










Table 7. Cox univariable regression analysis for the combined end point (heart failure 
hospitalization, cardiovascular death and cardiac transplantation). 
 HR (95% CI) 
 
P-value 
Age (per year) 0.99 (0.95-1.04) 0.847 
Male  1.62 (0.37-7.19) 0.525 
Ischaemic cardiomyopathy  2.48 (0.88-6.98) 0.085 
NYHA class II vs. III 2.08 (0.47-9.24) 0.334 
Log proBNP (per ng/L) 3.70 (1.21-11.27) 0.021 
Posterolateral vein (LV lead position) 0.91 (0.30-2.96) 0.917 
LBBB 0.32 (0.12-0.92) 0.033 
Pre-implant QRS duration (per 10 ms) 1.07 (1.04-1.11) 0.647 
Pre-implant QTc (per 10 ms) 1.02 (1.00-1.04) 0.812 
Pre-implant QRS axis (per 10°) 1.05 (1.04-1.06) 0.157 
Paced QRS duration (per  10 ms) 1.20 (1.17-1.23) 0.178 
Electrical remodelling 0.22 (0.05-0.98) 0.047 
LVEDV (per 10 mL) 1.07 (1.06-1.08) 0.047 
LVESV (per 10 mL) 1.10 (1.09-1.11) 0.023 
LVEF (per 10%) 0.38 (0.34-0.43) 0.097 
Echocardiographic response 0.13 (0.03-0.56) 0.006 
HR = hazard ratio; 95% CI = 95% confidence interval; NYHA class = New York Heart Association 
class; BNP = brain natriuretic peptide; LBBB = left bundle branch block; LVEF = left ventricular 
ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left ventricular end 





This doctor thesis demonstrated that some baseline ECG parameters from 12-leads ECG 
recording are associated with increased degree of echocardiographic response after CRT. 
Absolute post-implant QRS duration and acute relative shortening of QRS duration after 
initiation of CRT were correlated with super-response at 12-month follow-up. However, 
there were dynamic changes of repolarization parameters of native conduction during 12 
months after CRT. Increase repolarization heterogeneity in the first month after CRT 
corresponded with the high rate of VTs in the same periods. However, decline of both 
repolarization heterogeneity and VTs were noted after acute phase of biventricular pacing.  
Additionally, electrical remodelling of native conduction is achieved before mechanical 
remodelling. Patients with electrical remodelling had better clinical outcome compared with 
patients without electrical remodelling. 
I. The Association of Electrocardiographic Parameters from 12-Leads 
ECG and Response to Cardiac Resynchronization Therapy 
Several randomized studies have demonstrated echocardiographic improvement in heart 
failure patients treated with CRT.36,55 However, the degree of response to CRT is variable 
and certain proportion of patients experience a dramatic LV reverse remodelling after CRT, 
known as “super-response”. In the literature, different definitions of super-responders could 
be found ranging from a near-normalization or normalization of LVEF,56 an increase in 
LVEF of > 20%,41 a decrease in LVESV of ≥ 30% 33,34 to a combination of several 
parameters.57 LV remodelling after CRT is most often quantified by measuring the ESV. 




CRT.53 Therefore, we defined super-response as a decrease in LVESV of ≥ 30%.  Due to 
divergent definitions of super-responders, the proportion of super-responders varies from 13 
to 38%.34,57 However, the proportion of super-responders in our patient cohort was in the 
line with previous studies using similar definition of super-responders.33,34 Recently, Steffel 
at al. demonstrated that three definition of super-response (increase in EF ≥ 10%; a decrease 
in LVESV ≥ 30%; and a decrease in LVEDV ≥ 20%) were comparable regarding their ability 
to predict a favourable outcome after CRT.58 Nonetheless, lack of a universal definition of 
super-responders might account for different characteristics of patients with marked 
improvement of echocardiographic parameters undergoing CRT.   
Different pre-implant clinical and echocardiographic predictors of super-response have been 
identified in CRT patients (i.e. female gender, non-ischemic cardiomyopathy, lower 
proBNP, smaller baseline LV dimensions, mechanical dyssynchrony).33,34,41,59,60  Although 
our results show that super-responders had a lower proBNP and had a trend toward lower 
NYHA class, there were no differences in other baseline clinical and echocardiographic 
characteristics. In our study, apart from ECG parameters only NYHA class remained 
independently associated with super-response in multivariate model. These findings are in 
line with previous studies which indicated that mildly symptomatic HF (lower NYHA 
functional class) was associated with an increased likelihood of super-response.33,34 As 
mentioned before, varied definitions of super-responders could contribute to the various 
predictors of super-response. In addition, differences in study population characteristics and 
the time of echocardiographic follow-up assessment may also account for the discrepancy 
of the results. Earlier studies were in line with contemporary guidelines which did not 
include patients with NYHA functional class II.33,34,57 Therefore, we believe that our study 
population most closely resembles nowadays daily practice. Furthermore, time delay to 
follow-up echocardiogram varied greatly between studies, ranging from 2 to 12 months.41,59 
As LV reverse remodelling after CRT represents a progressive process with possible 
persistence of at least 9 months,36 earlier follow-ups might underestimate the number of 
super-responders.  
While echocardiographic parameters of dyssynchrony failed to predict CRT response,23 
some other parameters have been extensively researched. However, CRT is merely electrical 




electrical activation.61 Therefore, ECG parameters of electric dyssynchrony or their 
modifications seem to be better predictors of response. Previous studies found that LBBB 
morphology was related with reducing of all-cause mortality and HF hospitalization. 
Therefore, it not surprisingly that recent studies showed that LBBB morphology plays an 
important role in super-response to CRT.33,41,59 In contrast, no such correlations were evident 
from the data in our study. Predominant LBBB morphology of our study population could 
account for the discrepancy. In our study nearly 70% of patients had LBBB compared to 
43% in studies where LBBB was found as a predictor of super-response.41  
Furthermore, the predictive value of baseline QRS duration also remains controversial. 
Consistent with our results, some authors reported no added value of wider QRS 
complex.41,56,57 In contrast, several studies revealed significant association between wide 
QRS complex and super-response.33,59 Relatively broad QRS complex (average of 165 ms) 
in our study group could be the reason for lack of predictive value of this ECG parameter. 
There is limited data regarding other ECG parameters associated with super-responders. In 
our study, we identified two electrocardiographic variables associated with super-response: 
absolute post-implant QRS duration and acute relative shortening of QRS complex. Acute 
relative shortening of QRS complex > 4.5% (sensitivity of 81%, specificity of 58%) had a 
predictive value of super-response. Nevertheless, the recent result showed that combining 
baseline clinical, ECG and echocardiographic parameters improve predictive power for LV 
reverse remodelling than clinical and ECG parameters alone.62 Post-implant QRS duration 
and shortening of QRS complex have also been previously associated with overall 
improvement in cardiac remodelling in other studies of CRT,40,63–65 but no similar studies 
have been done for super-responders. In PROSPECT-ECG study, prediction of CRT 
response was associated with the difference between biventricular and pre-implant QRS 
duration (absolute shortening) and also post-implant QRS width.40 In addition, Rickard et al. 
postulated that the QRS change index was strongly associated with reverse remodelling in 
multivariate analysis.63 Nevertheless, ROC analysis produced no reliable sensitivity and 
specificity cut-off for the QRS change index. They used the percent of QRS change from 
baseline, termed as QRS change index, to take into account baseline differences in QRS 
duration. The same methodology was also used in our study. However, relative shortening 
of QRS duration seems to be a better parameter for predicting response then absolute 




could be affected by baseline QRS duration. Therefore accurate prediction based on direct 
reduction in QRS duration after CRT might be difficult.65 Molhoek et al. showed that a 
decrease in QRS duration immediately after the implantation and 6 months later was 
predictive of a clinical response to CRT. In addition, Lecoq et al. reported similar findings 
in the study where pacing leads were actively targeted to obtain the shortest QRS duration, 
and QRS shortening was the only independent predictor of CRT response.64 Acute QRS 
shortening could be therefore an easily obtainable ECG parameter for an early prediction of 
CRT response. However, the degree of QRS narrowing at the implant might be more 
important for response than the actual duration of the baseline wide QRS complex. In 
addition, inadequate shortening of the post-implant QRS duration could single out patients 
with potential worse outcome. Consequently, closer monitoring of these patients and 
additional therapeutic interventions (CRT optimization, reposition of LV lead or use of 
multiple LV leads, etc) could improve their outcomes.  
According to the pathophysiology of electromechanical disorders, the change in QRS 
duration produced by CRT should represent the quality of electrical resynchronization and 
might indirectly reflect the degree of correction of electromechanical abnormalities.61 Our 
results are in line with experimental studies of LBBB, where maximum improvement in LV 
pump function occurred when intra-left ventricular electric asynchrony was minimized by 
wavefront fusion.66 Greater QRS shortening after CRT may indicate a large degree of 
resynchronization associated with the quality of the myocardial substrate and the location of 
the LV pacing electrode.40,67 Pacing an area of scar with slower conduction might result in a 
wider paced QRS complex. Consequently, segments with scar tissue in the potential LV 
pacing site should be identified to avoid possible increase of duration of electrical 
conduction.40 However, further prospective clinical studies are warranted to determine 
whether optimization of paced QRS duration during implantation could result in additional 





II. The Effect of Cardiac Resynchronization Therapy on Ventricular 
Repolarization Parameters and their Relation to Ventricular 
Tachyarrhythmias 
Biventricular stimulation with LV epicardial pacing reverses the LV sequence of 
depolarization and repolarization, which might increase heterogeneity of repolarization 
intrinsic to ventricular myocardium, a substrate for ventricular arrhythmias.43,68 However, 
all randomised studies found a reduction of sudden cardiac death after CRT in patients with 
heart failure.4,69 On the other hand, data regarding the effect of biventricular pacing on 
ventricular repolarization are contradictory and mainly focused on repolarization parameters 
from pacing ECG recordings.43,47,70–73 From the results of animal models and computer 
stimulation it is known, that epicardial pacing reverses the direction of electrical activation 
of the LV wall, which leads to a prominent increase in QT and transmural dispersion of 
repolarization.43,68 Acutely increased repolarization parameters after switching to 
biventricular pacing and potentially promoted VTs were also reported in humans in case 
studies.43,74 Conversely, clinical trials have demonstrated decreased TpTe  or even 
time‑dependent effect on transmural dispersion of repolarization after CRT 
implantation.27,47,75  
Previous studies analysed repolarization parameters from pacing ECG, compared with our 
methodology, where we focused on intrinsic myocardial electrophysiology. Data about the 
effect of CRT on repolarization parameters of native conduction are limited.31,70,71,76 Authors 
reported either significant reduction in native QTc and TpTe three months after 
implantation76 or found no significant changes in native QTc after at least 12 months after 
CRT implantation.31,70 This effect of repolarization instability after initiation of biventricular 
pacing is not well defined in heart failure patients with structured remodelled heart and 
already altered ventricular activation due to conduction abnormalities. It is known, that an 
abrupt change in electrical activation sequence, which happened after initiation of pacing, 
results in ventricular repolarization instability lasted over days to weeks in structurally 
normal heart.77 We found significant dynamic changes of repolarization parameters of native 
conduction during 12 months after CRT, with the increase of repolarization heterogeneity in 
the first months after CRT, which then decline over further follow ups. Wecke et al. analysed 




results, they showed prolongation of cardiac repolarization, reflected by an increase in TpTe 
and QTc in the first 2 weeks after biventricular pacing. According to our results we can 
conclude, that CRT initiation potentially induces an increase in repolarization 
heterogeneities. It is conceivable that this effect might be more pronounced and could 
become clinically important in certain individuals with a reduced repolarization reserve.78 
However, we observed a decrease of repolarization heterogeneity in patients with LV 
volumetric remodelling after acute phase of biventricular pacing. These beneficial effects on 
repolarization heterogeneity could be a result of favourable LV reverse remodelling. In 
contrary, non-responder showed no significant improvement of repolarization heterogeneity 
over time after CRT implantation. Moreover, we noted even progressive increase of 
repolarization parameters at follow-ups compared with pre-implant value. As decrease of 
repolarization heterogeneity after acute phase of biventricular pacing was found only in the 
responder group, we speculated that LV remodelling should be the main mechanism which 
decreases the repolarization heterogeneity after further follow-ups. 
Whether CRT is associated with decrease VTs is unclear since previous studies have yielded 
conflicting results.79–81 Lin G, et al. and McSwain, et al. found that CRT had no effect on the 
frequency of VTs in patients who underwent upgrade form ICD.79,80 Whereas other results 
showed that arrhythmia frequency and number of appropriate ICD treatments were reduced 
after upgrade to CRT-D for HF treatment.81 On the other hand, patients with reverse 
remodelling after CRT had a lower incidence of VTs compared with patients without reverse 
remodelling.46,75,82,83 Authors of these studies concluded that the reduction in the frequency 
of VTs after CRT could be related to improved haemodynamic status as a consequence of 
ventricular reverse remodelling whereas other proposed decreased myocardial wall tension 
and electrical stabilization of myocyte membranes.84 All these trials focused on analysing 
long-term effect of CRT on VTs. However, data regarding the short or mid-term effect of 
CRT on occurrences of VTs are limited.75 To the best of our knowledge, there are no 
previous data regarding the relation between repolarization changes during native 
conduction and occurrence of VTs. We found that the largest number of patients experienced 
VTs within first month after CRT implantation, and then was a decrease in number of 
patients with VTs over first year after implantation. However, all patients with the VTs in 
the observed period were from primary prevention group. Moreover, the pattern of the 




changes. Therefore, we speculated that the increase in repolarization heterogeneity acutely 
after CRT could create the substrate for the development of VTs. In the acute phase, this 
abrupt change in electrical activation sequence caused by epicardial pacing might result in 
ventricular repolarization instability and consequently prolongation of the QT interval and 
increase repolarization heterogeneity, creating a substrate and trigger for arrhythmia. Based 
on our results, after initial phase of biventricular pacing decrease of repolarization 
heterogeneity was related with decrease incidents of VTs episodes. Wecke et al. proposed 
that after acute phase, electrical remodelling probably leads to an adaptation to the new 
activation sequence, presumably in an antiarrhythmic way.71 Similarly to our results, Itoh et 
al. also described time-dependent numbers of VTs after CRT with the highest rate of VTs in 
the first month.75 Contrary to previous mention studies, 46,75,82,83 we did not find significant 
difference in the numbers of VT and response to CRT. This discrepancy could be due to 
different follow-up and different observation period for arrhythmias. In our study, we 
focused only on the first year after CRT, therefore the effect of favourable ventricular 
remodelling after CRT might have not yet affected the occurrences of VTs. However, 
progressive reverse remodelling is time dependent process and can be detected up to three 
year after CRT implantation.36 Nevertheless, the numbers of VTs in short follow-up could 
also be too low to show statistical significance.  
To the best of our knowledge, this is the first study that analysed time-related effect of CRT 
on repolarization parameters of native conduction and its association with VTs. Our study 
shows that a potential pro-arrhythmic phase after initiation of CRT seems to be transient and 
can diminish over time with successful LV reverse remodelling. Future randomized studies 
on the current topic are therefore recommended in order to clarify the acute and chronic 
effect of biventricular pacing on repolarization heterogeneity and its relation on VTs.  
Ventricular repolarization duration is routinely assessed by measuring QT interval. 
However, in patients with wider QRS complex QT duration is affected also by conduction 
disturbances. There are continuous debate about which repolarization interval should be 
measured in patients with wide QRS complex.85,86 Therefore, besides QT intervals, 
additional parameters less dependent on ventricular depolarization alterations, such as TpTe 




III. Time Course and Relationship between Electrical and Mechanical 
Reverse Remodelling after Cardiac Resynchronization Therapy  
Several studies regarding CRT have focused on LV volume reduction and improvement of 
contractile function, termed reverse mechanical remodelling. In line with our results, recent 
studies assessing the time course of LV reverse remodelling after CRT showed progressive 
reduction of LV dimensions and improvement of LV function occurring after 3 months.36,87 
However, CRT is primarily an electrical therapy which improves LV mechanical function 
by changing the sequence of electrical activation.61 In the PROSPECT-ECG study, paced 
QRS width after initiation of CRT was associated with reverse LV mechanical remodelling 
and improved outcome.40 Although acute shortening of paced QRS duration after 
biventricular pacing could be interpreted as a sign of blunt rectification of electrical 
dyssynchrony, caution should be taken on its prognostic value. Firstly, QRS duration 
represents the fusion of propagation originating from different pacing sites. Secondly, 
changes in paced QRS duration are not uncommon with alterations in cardiac function, 
device optimization (settings of AV and VV delay) and myocardial excitability.61,88 Thus, it 
is conceivable that native QRS changes could be a better surrogate to assess ER after CRT.  
Published data on whether restitution of native conduction system is accompanied by 
recovery of LV dimension and function is scarce and nonuniform. Early studies by 
Stockburger et al.37 and Vogt et al.89 reported no change in native QRS duration after CRT. 
Coinciding with our results, more recent publications demonstrated significant native QRS 
narrowing after long-term biventricular pacing associated with reduction of LV volumes and 
improvement of LV function.31,42,90 
 However, the exact time course between ER of native conduction and improvement of LV 
mechanical remodelling has not yet been defined. To the best of our knowledge, this is the 
first prospective study showing that ER of native conduction precedes detectable LV 
structural changes after CRT. Our results showed that significant shortening of native QRS 
duration was already recognized after 1 month of CRT, persisting during further follow-ups, 
while echocardiographic LV changes were noted only after 3 month follow-up. In contrast, 
two similar studies by Yang et al.88 and Mischke et al.90 demonstrated that ER was already 




and our results progressive reduction of LV dimensions and improvement of LV function 
already occur after 3 months of CRT. Accordingly, it is conceivable to assume that more 
frequent and especially earlier follow-ups could account for the discrepancy of the results. 
Hypothetically, CRT might primarily ameliorate conduction abnormalities, which in turn 
lead to improvement of LV mechanical properties and consecutive recovery of LV 
dimensions.  
Sebage et al. presumed that CRT-induced changes in intrinsic QRS duration are probably 
the consequence of multiple factors including reduction in chamber dimensions and possibly 
changes in the conduction system.31 In our study, significant decrease of native QRS duration 
was observed before progressive reduction of LV volumes. Therefore, we speculated that 
ER of native conduction after CRT could not be predominantly due to anatomical reduction 
of LV, but as a result of changes in the conduction system with the correction of cardiac gap 
junction proteins, ion channel remodelling and the reversal of molecular alterations 
associated with dyssynchronous HF.91 However, further studies of the mechanisms of ER of 
native conduction are needed to confirm our hypothesis.  
Data regarding the effect of ER of native conduction on clinical outcome in patients with 
CRT are limited. In the literature, there is only one study that analysed the relationship of 
ER to survival rates.42 The authors found that ER was associated with a 4-fold decrease in 
the risk of death or appropriate ICD therapy. Comparably, in our study patients with ER had 







The doctor thesis have some limitations which might have influenced the results. The most 
important limitation of the studies is the small number of patients and low number of events, 
which could have influenced our inability to identify clinical outcome predictors. Patient 
cohort from this single centre study may not be representative of patients presenting in other 
centres. Measurement of QRS duration by using only lead V2 is not a standardized method, 
therefore calculating average QRS duration in all 12 leads might have diminished 
underestimation of QRS duration in one particular lead. Programmed AV and VV interval, 
which might affect LV reverse remodelling were not analysed in our study. Recently study 
showed that paced ventricular activation wavefront fusion increases the probability of 
reverse remodelling.29 This implies that failure to correct LV conduction delay, despite 
biventricular pacing, contributes significantly to volumetric non-response. Therefore, 
programming AV and VV delay might significantly alter quality of fusion and alter the 
duration and morphology of paced QRS complex. In addition, percentage of biventricular 
pacing and HF medication dosage could also be related to CRT response. Assessment of 
echocardiographic super-response was made during 12 month follow-up, which could miss 
a minority of patients with delayed reverse remodelling after CRT.60 Also relatively modest 
power of cut off value of relative QRS shortening of predicting super-response in our study 
could be improved in larger study cohort. Furthermore, echocardiographic outcomes do not 
always correlate well with clinical endpoints (cardiac mortality, HF hospitalization), which 
were not targeted in our study. Due to the relatively small sample size, differences in 
occurrence of VTs could not be determined in responders versus non-responders to CRT. 
An increased repolarization heterogeneity may particularly affect polymorphic arrhythmias 
whereas monomorphic VTs related to CRT could have a mechanism unrelated to 
repolarization heterogeneity, such as the creation of unidirectional block in zones of slow 
conduction within the scar tissue located in the LV.72 Small number of VTs in our study 
group did not allow such an analysis. The antiarrhythmic drugs and presence of myocardial 
fibrosis may significantly contribute repolarization heterogeneity but our study lacks power 
for these subgroup analyses. The definition of reverse ER of the native conduction is not 
consistent in the literature. However, we used previous defined cut off value of QRS 
narrowing of ≥ 10 ms as a marker of ER 42. Finally, relatively short follow-up period (median 




Therefore, also multivariable Cox proportional hazards analysis was not able to be done due 






Absolute post-implant QRS duration and acute relative shortening of QRS duration after 
initiation of biventricular pacing are associated with echocardiographic super-response after 
CRT at 12-month follow-up. Monitoring of these easily identifiable ECG parameters during 
device implantation could improve outcomes in patients undergoing CRT.   
There were dynamic changes of repolarization parameters of native conduction during 12 
months after CRT. Increase repolarization heterogeneity in the first month after CRT 
corresponded with the high rate of VTs in the same periods. However, left ventricular 
remodelling seems to be the main mechanism, which decreases the repolarization 
heterogeneity after further follow-ups. 
In CRT patients, ER of native conduction precedes detectable LV structural changes. It 
seems that only with CRT induced ER progressive mechanical reverse remodelling could be 
achieved. Our study showed that early detection of ER of native conduction is associated 
with better clinical outcome. Therefore, ECG assessment of the native QRS during short-
term follow-up period could be an alternative non-invasive clinical approach to identify 
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